RedShift BioAnalytics
Provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
$20.0m | Series E | ||
| Total Funding | 000k | ||
Related Content
RedShift BioAnalytics develops and manufactures analytical instruments for the life science and biopharmaceutical sectors. The company's product portfolio, which includes the Aurora, Apollo, and HaLCon systems, is designed to provide critical measurements in the development of protein-based drugs by enabling the structural analysis of biomolecules.
By combining microfluidics with tunable lasers, RedShift BioAnalytics' technology offers a platform for the reliable and accurate detection of changes in molecular structure, which are critical quality attributes that govern the stability and efficacy of protein therapeutics. The company serves research and development laboratories and biopharmaceutical companies, providing them with tools for rapid and precise analysis.
Keywords: analytical instruments, biomolecule analysis, protein-based drugs, life sciences, biopharmaceuticals, microfluidics, tunable lasers, structural analysis, molecular structure, protein therapeutics